ReP USP - Resultado da busca

Artigo de periodico
Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception (2025)
Giarolla, Jeanine ; Holdaway, Kelsey A ; Nazari, Maryam; Aiad, Laila; Sarkar, Bidisha; Georg, Gunda I
Fonte: Future Medicinal Chemistry. Unidade: FCF
Assuntos: LIGANTES, NEOPLASIAS, ENSAIO CLÍNICO, LIGANTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIAROLLA, Jeanine et al. Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception. Future Medicinal Chemistry, v. 17, n. 5, p. 607–627, 2025Tradução . . Disponível em: https://dx.doi.org/10.1080/17568919.2025.2463868. Acesso em: 08 out. 2025.
APA
Giarolla, J., Holdaway, K. A., Nazari, M., Aiad, L., Sarkar, B., & Georg, G. I. (2025). Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception. Future Medicinal Chemistry, 17( 5), 607–627. doi:10.1080/17568919.2025.2463868
NLM
Giarolla J, Holdaway KA, Nazari M, Aiad L, Sarkar B, Georg GI. Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception [Internet]. Future Medicinal Chemistry. 2025 ; 17( 5): 607–627.[citado 2025 out. 08 ] Available from: https://dx.doi.org/10.1080/17568919.2025.2463868
Vancouver
Giarolla J, Holdaway KA, Nazari M, Aiad L, Sarkar B, Georg GI. Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception [Internet]. Future Medicinal Chemistry. 2025 ; 17( 5): 607–627.[citado 2025 out. 08 ] Available from: https://dx.doi.org/10.1080/17568919.2025.2463868
Artigo de periodico-carta/editorial
SETDB1: an emerging target for anticancer drug development [Editorial] (2025)
Trossini, Gustavo Henrique Goulart ; Hassanie, Haifa ; Penteado, André Berndt ; Hajje, Marissa El
Fonte: Future Medicinal Chemistry. Unidade: FCF
Assuntos: NEOPLASIAS, PLANEJAMENTO DE FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TROSSINI, Gustavo Henrique Goulart et al. SETDB1: an emerging target for anticancer drug development [Editorial]. Future Medicinal Chemistry. London: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://dx.doi.org/10.1080/17568919.2024.2444869. Acesso em: 08 out. 2025. , 2025
APA
Trossini, G. H. G., Hassanie, H., Penteado, A. B., & Hajje, M. E. (2025). SETDB1: an emerging target for anticancer drug development [Editorial]. Future Medicinal Chemistry. London: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. doi:10.1080/17568919.2024.2444869
NLM
Trossini GHG, Hassanie H, Penteado AB, Hajje ME. SETDB1: an emerging target for anticancer drug development [Editorial] [Internet]. Future Medicinal Chemistry. 2025 ;( 2): 153–155.[citado 2025 out. 08 ] Available from: https://dx.doi.org/10.1080/17568919.2024.2444869
Vancouver
Trossini GHG, Hassanie H, Penteado AB, Hajje ME. SETDB1: an emerging target for anticancer drug development [Editorial] [Internet]. Future Medicinal Chemistry. 2025 ;( 2): 153–155.[citado 2025 out. 08 ] Available from: https://dx.doi.org/10.1080/17568919.2024.2444869
Artigo de periodico
The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs (2024)
Dobrachinski, Leandro; Ferreira, Leonardo Luiz Gomes ; Cirino, Maria Eduarda de; Siqueira, Allan Igor Andrade de ; Mafud, Ana Carolina ; Mascarenhas, Yvonne Primerano ; Andricopulo, Adriano Defini ; Moraes, Josué de
Fonte: Future Medicinal Chemistry. Unidade: IFSC
Assuntos: FÁRMACOS, PLANEJAMENTO DE FÁRMACOS, DOENÇAS PARASITÁRIAS, DOENÇA DE CHAGAS, TRYPANOSOMA CRUZI
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOBRACHINSKI, Leandro et al. The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs. Future Medicinal Chemistry, v. 16, n. 17, p. 1791-1799, 2024Tradução . . Disponível em: https://doi.org/10.1080/17568919.2024.2379231. Acesso em: 08 out. 2025.
APA
Dobrachinski, L., Ferreira, L. L. G., Cirino, M. E. de, Siqueira, A. I. A. de, Mafud, A. C., Mascarenhas, Y. P., et al. (2024). The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs. Future Medicinal Chemistry, 16( 17), 1791-1799. doi:10.1080/17568919.2024.2379231
NLM
Dobrachinski L, Ferreira LLG, Cirino ME de, Siqueira AIA de, Mafud AC, Mascarenhas YP, Andricopulo AD, Moraes J de. The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs [Internet]. Future Medicinal Chemistry. 2024 ; 16( 17): 1791-1799.[citado 2025 out. 08 ] Available from: https://doi.org/10.1080/17568919.2024.2379231
Vancouver
Dobrachinski L, Ferreira LLG, Cirino ME de, Siqueira AIA de, Mafud AC, Mascarenhas YP, Andricopulo AD, Moraes J de. The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs [Internet]. Future Medicinal Chemistry. 2024 ; 16( 17): 1791-1799.[citado 2025 out. 08 ] Available from: https://doi.org/10.1080/17568919.2024.2379231
Artigo de periodico-carta/editorial
Empowering neglected tropical disease drug discovery with translational medicinal chemistry. [Editorial] (2023)
Ferreira, Leonardo Luiz Gomes ; Andricopulo, Adriano Defini
Fonte: Future Medicinal Chemistry. Unidade: IFSC
Assuntos: DOENÇAS NEGLIGENCIADAS, PLANEJAMENTO DE FÁRMACOS, QUÍMICA MÉDICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERREIRA, Leonardo Luiz Gomes e ANDRICOPULO, Adriano Defini. Empowering neglected tropical disease drug discovery with translational medicinal chemistry. [Editorial]. Future Medicinal Chemistry. London: Instituto de Física de São Carlos, Universidade de São Paulo. Disponível em: https://doi.org/10.4155/fmc-2023-0140. Acesso em: 08 out. 2025. , 2023
APA
Ferreira, L. L. G., & Andricopulo, A. D. (2023). Empowering neglected tropical disease drug discovery with translational medicinal chemistry. [Editorial]. Future Medicinal Chemistry. London: Instituto de Física de São Carlos, Universidade de São Paulo. doi:10.4155/fmc-2023-0140
NLM
Ferreira LLG, Andricopulo AD. Empowering neglected tropical disease drug discovery with translational medicinal chemistry. [Editorial] [Internet]. Future Medicinal Chemistry. 2023 ; 15( 12): 1015-1017.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2023-0140
Vancouver
Ferreira LLG, Andricopulo AD. Empowering neglected tropical disease drug discovery with translational medicinal chemistry. [Editorial] [Internet]. Future Medicinal Chemistry. 2023 ; 15( 12): 1015-1017.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2023-0140
Artigo de periodico
Human sirtuin 2 inhibitors, their mechanisms and binding modes (2023)
Penteado, André Berndt ; Hassanie, Haifa ; Gomes, Renan Augusto ; Emery, Flavio da Silva ; Trossini, Gustavo Henrique Goulart
Fonte: Future Medicinal Chemistry. Unidades: FCFRP, FCF
Assuntos: METABOLISMO, PLANEJAMENTO DE FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PENTEADO, André Berndt et al. Human sirtuin 2 inhibitors, their mechanisms and binding modes. Future Medicinal Chemistry, v. 15, n. 3, p. 291-311, 2023Tradução . . Disponível em: https://doi.org/10.4155/fmc-2022-0253. Acesso em: 08 out. 2025.
APA
Penteado, A. B., Hassanie, H., Gomes, R. A., Emery, F. da S., & Trossini, G. H. G. (2023). Human sirtuin 2 inhibitors, their mechanisms and binding modes. Future Medicinal Chemistry, 15( 3), 291-311. doi:10.4155/fmc-2022-0253
NLM
Penteado AB, Hassanie H, Gomes RA, Emery F da S, Trossini GHG. Human sirtuin 2 inhibitors, their mechanisms and binding modes [Internet]. Future Medicinal Chemistry. 2023 ; 15( 3): 291-311.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2022-0253
Vancouver
Penteado AB, Hassanie H, Gomes RA, Emery F da S, Trossini GHG. Human sirtuin 2 inhibitors, their mechanisms and binding modes [Internet]. Future Medicinal Chemistry. 2023 ; 15( 3): 291-311.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2022-0253
Artigo de periodico
New kinase and HDAC hybrid inhibitors: recent advances and perspectives (2022)
Waitman, Karoline; Parise Filho, Roberto
Fonte: Future Medicinal Chemistry. Unidade: FCF
Assuntos: NEOPLASIAS, ESTRATÉGIAS TERAPÊUTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WAITMAN, Karoline e PARISE FILHO, Roberto. New kinase and HDAC hybrid inhibitors: recent advances and perspectives. Future Medicinal Chemistry, v. 14, n. 10, p. 1-2, 2022Tradução . . Disponível em: https://doi.org/10.4155/fmc-2021-0276. Acesso em: 08 out. 2025.
APA
Waitman, K., & Parise Filho, R. (2022). New kinase and HDAC hybrid inhibitors: recent advances and perspectives. Future Medicinal Chemistry, 14( 10), 1-2. doi:10.4155/fmc-2021-0276
NLM
Waitman K, Parise Filho R. New kinase and HDAC hybrid inhibitors: recent advances and perspectives [Internet]. Future Medicinal Chemistry. 2022 ; 14( 10): 1-2.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2021-0276
Vancouver
Waitman K, Parise Filho R. New kinase and HDAC hybrid inhibitors: recent advances and perspectives [Internet]. Future Medicinal Chemistry. 2022 ; 14( 10): 1-2.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2021-0276
Artigo de periodico
Novel trypanocidal thiophen-chalcone cruzain inhibitors: structure- and ligand-based studies (2022)
Oliveira, Aldo Sena de ; Valli, Marilia ; Ferreira, Leonardo Luiz Gomes ; Souza, Julia Medeiros ; Andricopulo, Renata Krogh; Meier, Lidiane; Abreu, Heitor R.; Voltolini, Bruna G.; Llanes, Luana C.; Nunes, Ricardo José; Braga, Antonio L.; Andricopulo, Adriano Defini
Fonte: Future Medicinal Chemistry. Unidade: IFSC
Assuntos: FÁRMACOS, PLANEJAMENTO DE FÁRMACOS, DOENÇAS PARASITÁRIAS, DOENÇA DE CHAGAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Aldo Sena de et al. Novel trypanocidal thiophen-chalcone cruzain inhibitors: structure- and ligand-based studies. Future Medicinal Chemistry, v. 14, n. 11, p. 795-808, 2022Tradução . . Disponível em: https://doi.org/10.4155/fmc-2022-0013. Acesso em: 08 out. 2025.
APA
Oliveira, A. S. de, Valli, M., Ferreira, L. L. G., Souza, J. M., Andricopulo, R. K., Meier, L., et al. (2022). Novel trypanocidal thiophen-chalcone cruzain inhibitors: structure- and ligand-based studies. Future Medicinal Chemistry, 14( 11), 795-808. doi:10.4155/fmc-2022-0013
NLM
Oliveira AS de, Valli M, Ferreira LLG, Souza JM, Andricopulo RK, Meier L, Abreu HR, Voltolini BG, Llanes LC, Nunes RJ, Braga AL, Andricopulo AD. Novel trypanocidal thiophen-chalcone cruzain inhibitors: structure- and ligand-based studies [Internet]. Future Medicinal Chemistry. 2022 ; 14( 11): 795-808.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2022-0013
Vancouver
Oliveira AS de, Valli M, Ferreira LLG, Souza JM, Andricopulo RK, Meier L, Abreu HR, Voltolini BG, Llanes LC, Nunes RJ, Braga AL, Andricopulo AD. Novel trypanocidal thiophen-chalcone cruzain inhibitors: structure- and ligand-based studies [Internet]. Future Medicinal Chemistry. 2022 ; 14( 11): 795-808.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2022-0013
Artigo de periodico
Diaminomaleonitrile derivatives as new potential antichagasic compounds: a study of structure-activity relationships (2021)
Oliveira, Aldo S. ; Mello, Lucas dos S. ; Ogihara, Camila H.; Döring, Thiago H. ; Palomino-Salcedo, David Leandro ; Duarte, Simone Michelan ; Ferreira, Leonardo Luiz Gomes ; Souza, Julia Medeiros ; Dávila-Rodríguez, María-José ; Cruz Júnior, José W. da ; Dockal, Edward R. ; Andricopulo, Adriano Defini
Fonte: Future Medicinal Chemistry. Unidade: IFSC
Assuntos: FÁRMACOS, PLANEJAMENTO DE FÁRMACOS, DOENÇAS PARASITÁRIAS, DOENÇA DE CHAGAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Aldo S. et al. Diaminomaleonitrile derivatives as new potential antichagasic compounds: a study of structure-activity relationships. Future Medicinal Chemistry, v. 13, n. 24, p. 2167-2183, 2021Tradução . . Disponível em: https://doi.org/10.4155/fmc-2021-0194. Acesso em: 08 out. 2025.
APA
Oliveira, A. S., Mello, L. dos S., Ogihara, C. H., Döring, T. H., Palomino-Salcedo, D. L., Duarte, S. M., et al. (2021). Diaminomaleonitrile derivatives as new potential antichagasic compounds: a study of structure-activity relationships. Future Medicinal Chemistry, 13( 24), 2167-2183. doi:10.4155/fmc-2021-0194
NLM
Oliveira AS, Mello L dos S, Ogihara CH, Döring TH, Palomino-Salcedo DL, Duarte SM, Ferreira LLG, Souza JM, Dávila-Rodríguez M-J, Cruz Júnior JW da, Dockal ER, Andricopulo AD. Diaminomaleonitrile derivatives as new potential antichagasic compounds: a study of structure-activity relationships [Internet]. Future Medicinal Chemistry. 2021 ; 13( 24): 2167-2183.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2021-0194
Vancouver
Oliveira AS, Mello L dos S, Ogihara CH, Döring TH, Palomino-Salcedo DL, Duarte SM, Ferreira LLG, Souza JM, Dávila-Rodríguez M-J, Cruz Júnior JW da, Dockal ER, Andricopulo AD. Diaminomaleonitrile derivatives as new potential antichagasic compounds: a study of structure-activity relationships [Internet]. Future Medicinal Chemistry. 2021 ; 13( 24): 2167-2183.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2021-0194
Artigo de periodico
Parasitic sirtuin 2 as an opportunity in drug discovery (2021)
Gomes, Renan Augusto ; Fornari, Evelin; Rocha, Ana Carolina Silva; Tripodi, Gustavo Luis; Emery, Flavio da Silva ; Trossini, Gustavo Henrique Goulart
Fonte: Future Medicinal Chemistry. Unidades: FCFRP, FCF
Assuntos: ANTIPROTOZOÁRIOS, EPIGÊNESE GENÉTICA, DOENÇAS INFECCIOSAS, PLANEJAMENTO DE FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOMES, Renan Augusto et al. Parasitic sirtuin 2 as an opportunity in drug discovery. Future Medicinal Chemistry, v. 13, n. 16, p. 1397-1409, 2021Tradução . . Disponível em: https://doi.org/10.4155/fmc-2021-0091. Acesso em: 08 out. 2025.
APA
Gomes, R. A., Fornari, E., Rocha, A. C. S., Tripodi, G. L., Emery, F. da S., & Trossini, G. H. G. (2021). Parasitic sirtuin 2 as an opportunity in drug discovery. Future Medicinal Chemistry, 13( 16), 1397-1409. doi:10.4155/fmc-2021-0091
NLM
Gomes RA, Fornari E, Rocha ACS, Tripodi GL, Emery F da S, Trossini GHG. Parasitic sirtuin 2 as an opportunity in drug discovery [Internet]. Future Medicinal Chemistry. 2021 ; 13( 16): 1397-1409.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2021-0091
Vancouver
Gomes RA, Fornari E, Rocha ACS, Tripodi GL, Emery F da S, Trossini GHG. Parasitic sirtuin 2 as an opportunity in drug discovery [Internet]. Future Medicinal Chemistry. 2021 ; 13( 16): 1397-1409.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2021-0091
Artigo de periodico
Synthesis, biochemical evaluation and molecular modeling studies of nonpeptidic nitrile-based fluorinated compounds (2021)
Lameiro, Rafael da Fonseca; Shamim, Anwar ; Rosini, Fabiana; Cendron, Rodrigo; Batista, Pedro Henrique Jatai ; Montanari, Carlos Alberto
Fonte: Future Medicinal Chemistry. Unidade: IQSC
Assuntos: DOENÇA DE CHAGAS, LEISHMANIA MEXICANA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LAMEIRO, Rafael da Fonseca et al. Synthesis, biochemical evaluation and molecular modeling studies of nonpeptidic nitrile-based fluorinated compounds. Future Medicinal Chemistry, v. 13, n. 1, p. 25–43, 2021Tradução . . Disponível em: https://doi.org/10.4155/fmc-2020-0057. Acesso em: 08 out. 2025.
APA
Lameiro, R. da F., Shamim, A., Rosini, F., Cendron, R., Batista, P. H. J., & Montanari, C. A. (2021). Synthesis, biochemical evaluation and molecular modeling studies of nonpeptidic nitrile-based fluorinated compounds. Future Medicinal Chemistry, 13( 1), 25–43. doi:10.4155/fmc-2020-0057
NLM
Lameiro R da F, Shamim A, Rosini F, Cendron R, Batista PHJ, Montanari CA. Synthesis, biochemical evaluation and molecular modeling studies of nonpeptidic nitrile-based fluorinated compounds [Internet]. Future Medicinal Chemistry. 2021 ; 13( 1): 25–43.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2020-0057
Vancouver
Lameiro R da F, Shamim A, Rosini F, Cendron R, Batista PHJ, Montanari CA. Synthesis, biochemical evaluation and molecular modeling studies of nonpeptidic nitrile-based fluorinated compounds [Internet]. Future Medicinal Chemistry. 2021 ; 13( 1): 25–43.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2020-0057
Artigo de periodico
New evidence for tamoxifen as an antischistosomal agent: in vitro, in vivo and target fishing studies (2021)
Silva, Tais C.; Mengarda, Ana C.; Silva, Bianca C.; Relvas-Lima, Thais S.; Rodrigues, Vinicius C.; Salvadori, M. C. ; Teixeira, Fernanda S.; Lopes, Andrey F. S.; Rando, Daniela G. G.; Moraes, Josué de
Fonte: Future Medicinal Chemistry. Unidade: IF
Assuntos: FÍSICO-QUÍMICA, BIOFÍSICA, FARMACOLOGIA, ESQUISTOSSOMOSE, SCHISTOSOMA MANSONI, ANTIPARASITÁRIOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Tais C. et al. New evidence for tamoxifen as an antischistosomal agent: in vitro, in vivo and target fishing studies. Future Medicinal Chemistry, v. 13, n. 11, 2021Tradução . . Disponível em: https://doi.org/10.4155/fmc-2020-0311. Acesso em: 08 out. 2025.
APA
Silva, T. C., Mengarda, A. C., Silva, B. C., Relvas-Lima, T. S., Rodrigues, V. C., Salvadori, M. C., et al. (2021). New evidence for tamoxifen as an antischistosomal agent: in vitro, in vivo and target fishing studies. Future Medicinal Chemistry, 13( 11). doi:10.4155/fmc-2020-0311
NLM
Silva TC, Mengarda AC, Silva BC, Relvas-Lima TS, Rodrigues VC, Salvadori MC, Teixeira FS, Lopes AFS, Rando DGG, Moraes J de. New evidence for tamoxifen as an antischistosomal agent: in vitro, in vivo and target fishing studies [Internet]. Future Medicinal Chemistry. 2021 ; 13( 11):[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2020-0311
Vancouver
Silva TC, Mengarda AC, Silva BC, Relvas-Lima TS, Rodrigues VC, Salvadori MC, Teixeira FS, Lopes AFS, Rando DGG, Moraes J de. New evidence for tamoxifen as an antischistosomal agent: in vitro, in vivo and target fishing studies [Internet]. Future Medicinal Chemistry. 2021 ; 13( 11):[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2020-0311
Artigo de periodico
Advanced drug delivery systems targeting NF-κB in respiratory diseases (2021)
Prasher, Parteek ; Sharma, Mousmee ; Chellappan, Dinesh Kumar ; Gupta, Gaurav ; Jha, Niraj Kumar; Singh, Sachin Kumar; MacLoughlin, Ronan ; Pinto, Terezinha de Jesus Andreoli ; Löbenberg, Raimar ; Dua, Kamal
Fonte: Future Medicinal Chemistry. Unidade: FCF
Assuntos: DOENÇAS RESPIRATÓRIAS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PRASHER, Parteek et al. Advanced drug delivery systems targeting NF-κB in respiratory diseases. Future Medicinal Chemistry, v. 13, n. 13, p. 1087-1090, 2021Tradução . . Disponível em: https://doi.org/10.4155/fmc-2021-0013. Acesso em: 08 out. 2025.
APA
Prasher, P., Sharma, M., Chellappan, D. K., Gupta, G., Jha, N. K., Singh, S. K., et al. (2021). Advanced drug delivery systems targeting NF-κB in respiratory diseases. Future Medicinal Chemistry, 13( 13), 1087-1090. doi:10.4155/fmc-2021-0013
NLM
Prasher P, Sharma M, Chellappan DK, Gupta G, Jha NK, Singh SK, MacLoughlin R, Pinto T de JA, Löbenberg R, Dua K. Advanced drug delivery systems targeting NF-κB in respiratory diseases [Internet]. Future Medicinal Chemistry. 2021 ; 13( 13): 1087-1090.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2021-0013
Vancouver
Prasher P, Sharma M, Chellappan DK, Gupta G, Jha NK, Singh SK, MacLoughlin R, Pinto T de JA, Löbenberg R, Dua K. Advanced drug delivery systems targeting NF-κB in respiratory diseases [Internet]. Future Medicinal Chemistry. 2021 ; 13( 13): 1087-1090.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2021-0013
Artigo de periodico
Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening (2021)
Federico, Leonardo Bruno ; Silva, Guilherme Martins da ; Melim, Lorane Izabel da Silva Hage; Gomes, Suzane Quintana ; Barcelos, Mariana Pegrucci ; Francischini, Isaque Antônio Galindo ; Silva, Carlos Henrique Tomich de Paula da
Fonte: Future Medicinal Chemistry. Unidades: FCFRP, FFCLRP
Assuntos: ANTIVIRAIS, MEDICAMENTO, COVID-19, BANCO DE DADOS, AVALIAÇÃO DE MEDICAMENTOS, ESTRUTURA MOLECULAR (QUÍMICA TEÓRICA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FEDERICO, Leonardo Bruno et al. Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening. Future Medicinal Chemistry, v. 13, n. 16, p. 1353-1366, 2021Tradução . . Disponível em: https://doi.org/10.4155/fmc-2021-0025. Acesso em: 08 out. 2025.
APA
Federico, L. B., Silva, G. M. da, Melim, L. I. da S. H., Gomes, S. Q., Barcelos, M. P., Francischini, I. A. G., & Silva, C. H. T. de P. da. (2021). Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening. Future Medicinal Chemistry, 13( 16), 1353-1366. doi:10.4155/fmc-2021-0025
NLM
Federico LB, Silva GM da, Melim LI da SH, Gomes SQ, Barcelos MP, Francischini IAG, Silva CHT de P da. Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening [Internet]. Future Medicinal Chemistry. 2021 ; 13( 16): 1353-1366.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2021-0025
Vancouver
Federico LB, Silva GM da, Melim LI da SH, Gomes SQ, Barcelos MP, Francischini IAG, Silva CHT de P da. Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening [Internet]. Future Medicinal Chemistry. 2021 ; 13( 16): 1353-1366.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2021-0025
Artigo de periodico
A novel scaffold to fight Pseudomonas aeruginosa pyocyanin production: early steps to novel antivirulence drugs (2020)
Froes, Thamires Quadros ; Guido, Rafael Victorio Carvalho ; Metwally, Kamel; Castilho, Marcelo Santos
Fonte: Future Medicinal Chemistry. Unidade: IFSC
Assuntos: PSEUDOMONAS, BIOQUÍMICA, PLANEJAMENTO DE FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FROES, Thamires Quadros et al. A novel scaffold to fight Pseudomonas aeruginosa pyocyanin production: early steps to novel antivirulence drugs. Future Medicinal Chemistry, v. 12, n. 16, p. 1489-1503, 2020Tradução . . Disponível em: https://doi.org/10.4155/fmc-2019-0351. Acesso em: 08 out. 2025.
APA
Froes, T. Q., Guido, R. V. C., Metwally, K., & Castilho, M. S. (2020). A novel scaffold to fight Pseudomonas aeruginosa pyocyanin production: early steps to novel antivirulence drugs. Future Medicinal Chemistry, 12( 16), 1489-1503. doi:10.4155/fmc-2019-0351
NLM
Froes TQ, Guido RVC, Metwally K, Castilho MS. A novel scaffold to fight Pseudomonas aeruginosa pyocyanin production: early steps to novel antivirulence drugs [Internet]. Future Medicinal Chemistry. 2020 ; 12( 16): 1489-1503.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2019-0351
Vancouver
Froes TQ, Guido RVC, Metwally K, Castilho MS. A novel scaffold to fight Pseudomonas aeruginosa pyocyanin production: early steps to novel antivirulence drugs [Internet]. Future Medicinal Chemistry. 2020 ; 12( 16): 1489-1503.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2019-0351
Artigo de periodico-carta/editorial
From chemoinformatics to deep learning: an open road to drug discovery. [Editorial] (2019)
Ferreira, Leonardo Luiz Gomes ; Andricopulo, Adriano Defini
Fonte: Future Medicinal Chemistry. Unidade: IFSC
Assuntos: APRENDIZADO COMPUTACIONAL, PLANEJAMENTO DE FÁRMACOS, INTELIGÊNCIA ARTIFICIAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERREIRA, Leonardo Luiz Gomes e ANDRICOPULO, Adriano Defini. From chemoinformatics to deep learning: an open road to drug discovery. [Editorial]. Future Medicinal Chemistry. London: Instituto de Física de São Carlos, Universidade de São Paulo. Disponível em: https://doi.org/10.4155/fmc-2018-0449. Acesso em: 08 out. 2025. , 2019
APA
Ferreira, L. L. G., & Andricopulo, A. D. (2019). From chemoinformatics to deep learning: an open road to drug discovery. [Editorial]. Future Medicinal Chemistry. London: Instituto de Física de São Carlos, Universidade de São Paulo. doi:10.4155/fmc-2018-0449
NLM
Ferreira LLG, Andricopulo AD. From chemoinformatics to deep learning: an open road to drug discovery. [Editorial] [Internet]. Future Medicinal Chemistry. 2019 ; 11( 5): 371-374.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2018-0449
Vancouver
Ferreira LLG, Andricopulo AD. From chemoinformatics to deep learning: an open road to drug discovery. [Editorial] [Internet]. Future Medicinal Chemistry. 2019 ; 11( 5): 371-374.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2018-0449
Artigo de periodico
Indole-3-glyoxyl tyrosine: synthesis and antimalarial activity against Plasmodium falciparum (2019)
Vasconcelos, Stanley Nunes Siqueira ; Meissner, Kamila Anna ; Ferraz, Witor Ribeiro ; Trossini, Gustavo Henrique Goulart ; Wrenger, Carsten ; Stefani, Hélio Alexandre
Fonte: Future Medicinal Chemistry. Unidades: FCF, ICB
Assuntos: MALÁRIA, PLASMODIUM FALCIPARUM, PROTOZOA, ANTIMALÁRICOS, ANIMAIS PARASITOS, VIRULÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VASCONCELOS, Stanley Nunes Siqueira et al. Indole-3-glyoxyl tyrosine: synthesis and antimalarial activity against Plasmodium falciparum. Future Medicinal Chemistry, v. 11, n. 6, p. 525-538, 2019Tradução . . Disponível em: https://doi.org/10.4155/fmc-2018-0246. Acesso em: 08 out. 2025.
APA
Vasconcelos, S. N. S., Meissner, K. A., Ferraz, W. R., Trossini, G. H. G., Wrenger, C., & Stefani, H. A. (2019). Indole-3-glyoxyl tyrosine: synthesis and antimalarial activity against Plasmodium falciparum. Future Medicinal Chemistry, 11( 6), 525-538. doi:10.4155/fmc-2018-0246
NLM
Vasconcelos SNS, Meissner KA, Ferraz WR, Trossini GHG, Wrenger C, Stefani HA. Indole-3-glyoxyl tyrosine: synthesis and antimalarial activity against Plasmodium falciparum [Internet]. Future Medicinal Chemistry. 2019 ; 11( 6): 525-538.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2018-0246
Vancouver
Vasconcelos SNS, Meissner KA, Ferraz WR, Trossini GHG, Wrenger C, Stefani HA. Indole-3-glyoxyl tyrosine: synthesis and antimalarial activity against Plasmodium falciparum [Internet]. Future Medicinal Chemistry. 2019 ; 11( 6): 525-538.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2018-0246
Artigo de periodico
Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei (2019)
Pereira, Glaécia A. N.; Santos, Lucianna H.; Wang, Steven C.; Martins, Luan C.; Villela, Filipe S.; Liao, Weiting; Dessoy, Marco A.; Dias, Luiz C.; Andricopulo, Adriano Defini ; Costa, Mariana A. F.; Nagem, Ronaldo A. P.; Caffrey, Conor R.; Liedl, Klaus R.; Caffarena, Ernesto R.; Ferreira, Rafaela S.
Fonte: Future Medicinal Chemistry. Unidade: IFSC
Assuntos: TRYPANOSOMA, PLANEJAMENTO DE FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PEREIRA, Glaécia A. N. et al. Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei. Future Medicinal Chemistry, v. 11, n. 13, p. 1537-1551, 2019Tradução . . Disponível em: https://doi.org/10.4155/fmc-2018-0523. Acesso em: 08 out. 2025.
APA
Pereira, G. A. N., Santos, L. H., Wang, S. C., Martins, L. C., Villela, F. S., Liao, W., et al. (2019). Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei. Future Medicinal Chemistry, 11( 13), 1537-1551. doi:10.4155/fmc-2018-0523
NLM
Pereira GAN, Santos LH, Wang SC, Martins LC, Villela FS, Liao W, Dessoy MA, Dias LC, Andricopulo AD, Costa MAF, Nagem RAP, Caffrey CR, Liedl KR, Caffarena ER, Ferreira RS. Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei [Internet]. Future Medicinal Chemistry. 2019 ; 11( 13): 1537-1551.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2018-0523
Vancouver
Pereira GAN, Santos LH, Wang SC, Martins LC, Villela FS, Liao W, Dessoy MA, Dias LC, Andricopulo AD, Costa MAF, Nagem RAP, Caffrey CR, Liedl KR, Caffarena ER, Ferreira RS. Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei [Internet]. Future Medicinal Chemistry. 2019 ; 11( 13): 1537-1551.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2018-0523
Artigo de periodico
Synthesis, leishmanicidal activity, structural descriptors and structure–activity relationship of quinoline derivatives (2018)
Silva, Etyene J. G; Souza, Adriana Bezerra; Passero, Luiz F. D; Laurenti, Marcia Dalastra; Ferreira, Glaucio Monteiro; Fujii, Drielli Gomes Vital; Trossini, Gustavo Henrique Goulart ; Raminelli, Cristiano
Fonte: Future Medicinal Chemistry. Unidades: FM, FCF
Assuntos: LEISHMANIA, MODELAGEM MOLECULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Etyene J. G et al. Synthesis, leishmanicidal activity, structural descriptors and structure–activity relationship of quinoline derivatives. Future Medicinal Chemistry, v. 10, n. 17, p. 2069-2085, 2018Tradução . . Disponível em: https://doi.org/10.4155/fmc-2018-0124. Acesso em: 08 out. 2025.
APA
Silva, E. J. G., Souza, A. B., Passero, L. F. D., Laurenti, M. D., Ferreira, G. M., Fujii, D. G. V., et al. (2018). Synthesis, leishmanicidal activity, structural descriptors and structure–activity relationship of quinoline derivatives. Future Medicinal Chemistry, 10( 17), 2069-2085. doi:10.4155/fmc-2018-0124
NLM
Silva EJG, Souza AB, Passero LFD, Laurenti MD, Ferreira GM, Fujii DGV, Trossini GHG, Raminelli C. Synthesis, leishmanicidal activity, structural descriptors and structure–activity relationship of quinoline derivatives [Internet]. Future Medicinal Chemistry. 2018 ; 10( 17): 2069-2085.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2018-0124
Vancouver
Silva EJG, Souza AB, Passero LFD, Laurenti MD, Ferreira GM, Fujii DGV, Trossini GHG, Raminelli C. Synthesis, leishmanicidal activity, structural descriptors and structure–activity relationship of quinoline derivatives [Internet]. Future Medicinal Chemistry. 2018 ; 10( 17): 2069-2085.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2018-0124
Artigo de periodico
Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure–activity relationship analyses (2017)
Kronenberger, Thales; Asse Junior, Leonardo Rander; Wrenger, Carsten ; Trossini, Gustavo Henrique Goulart ; Honorio, Kathia Maria; Maltarollo, Vinícius Gonçalves
Fonte: Future Medicinal Chemistry. Unidades: EACH, ICB, FCF
Assuntos: STAPHYLOCOCCUS, RELAÇÕES QUANTITATIVAS ENTRE ESTRUTURA QUÍMICA E ATIVIDADE BIOLÓGICA, MODELAGEM MOLECULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KRONENBERGER, Thales et al. Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure–activity relationship analyses. Future Medicinal Chemistry, v. 9, n. 2, p. 135-151, 2017Tradução . . Disponível em: https://doi.org/10.4155/fmc-2016-0179. Acesso em: 08 out. 2025.
APA
Kronenberger, T., Asse Junior, L. R., Wrenger, C., Trossini, G. H. G., Honorio, K. M., & Maltarollo, V. G. (2017). Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure–activity relationship analyses. Future Medicinal Chemistry, 9( 2), 135-151. doi:10.4155/fmc-2016-0179
NLM
Kronenberger T, Asse Junior LR, Wrenger C, Trossini GHG, Honorio KM, Maltarollo VG. Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure–activity relationship analyses [Internet]. Future Medicinal Chemistry. 2017 ; 9( 2): 135-151.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2016-0179
Vancouver
Kronenberger T, Asse Junior LR, Wrenger C, Trossini GHG, Honorio KM, Maltarollo VG. Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure–activity relationship analyses [Internet]. Future Medicinal Chemistry. 2017 ; 9( 2): 135-151.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2016-0179
Artigo de periodico
Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors (2017)
Pauli, Ivani; Ferreira, Leonardo Luiz Gomes ; Souza, Mariana L.; Oliva, Glaucius ; Ferreira, Rafaela S.; Dessoy, Marco A.; Slafer, Brian W.; Dias, Luiz C.; Andricopulo, Adriano Defini
Fonte: Future Medicinal Chemistry. Unidade: IFSC
Assuntos: DOENÇA DE CHAGAS, TRYPANOSOMA CRUZI, MODELAGEM MOLECULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PAULI, Ivani et al. Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors. Future Medicinal Chemistry, v. 9, n. 7, p. 641-657, 2017Tradução . . Disponível em: https://doi.org/10.4155/fmc-2016-0236. Acesso em: 08 out. 2025.
APA
Pauli, I., Ferreira, L. L. G., Souza, M. L., Oliva, G., Ferreira, R. S., Dessoy, M. A., et al. (2017). Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors. Future Medicinal Chemistry, 9( 7), 641-657. doi:10.4155/fmc-2016-0236
NLM
Pauli I, Ferreira LLG, Souza ML, Oliva G, Ferreira RS, Dessoy MA, Slafer BW, Dias LC, Andricopulo AD. Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors [Internet]. Future Medicinal Chemistry. 2017 ; 9( 7): 641-657.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2016-0236
Vancouver
Pauli I, Ferreira LLG, Souza ML, Oliva G, Ferreira RS, Dessoy MA, Slafer BW, Dias LC, Andricopulo AD. Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors [Internet]. Future Medicinal Chemistry. 2017 ; 9( 7): 641-657.[citado 2025 out. 08 ] Available from: https://doi.org/10.4155/fmc-2016-0236

Unidades USP

ReP

Filtros

Unidades USP

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

Grupo de pesquisa

Agência de fomento

Indexado em

Afiliação dos autores externos normalizada

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos